The US Food and Drug Administration has moved into full enforcement of the Drug Supply Chain Security Act after an 18-month stabilisation grace period concluded.
The enforcement shift marks a significant turning point for the pharmaceutical industry, which has spent years preparing for mandatory electronic, serialised data exchange requirements.
DSCSA now requires all trading partners to exchange transaction information, history, and statements electronically via EPCIS, a standardised data-sharing protocol for supply chain traceability.
Manufacturers and repackagers faced the earliest deadline, with a requirement to implement interoperable data exchange and package-level traceability by 27 May.
Wholesale distributors were given until 27 August to meet requirements for serialised data sharing and verification system compliance, marking the formal close of the FDA’s stabilisation window.
Dispensers with 26 or more full-time employees face a compliance deadline of 27 November 2025, while smaller dispensing operations have until 27 November 2026 to meet requirements.
The industry has broadly risen to the challenge, with reports indicating a 90 to 95 percent success rate in electronic data exchange across trading partners.
However, exception handling and master data management continue to pose difficulties for many organisations operating within the pharmaceutical supply chain.
A shipment placed on hold because it cannot be verified is not simply a compliance issue, as it can delay life-saving medicines, cause product to be rejected or destroyed, and generate costly returns and dispute fees.
The stakes of non-compliance have therefore grown considerably, with the supply chain described as more secure but also significantly less forgiving of errors or system failures.
Trading partners are being urged to invest in robust exception management processes to prevent data mismatches, missing serial numbers, or system downtime from stalling product flow.
The transition to full traceability represents the most substantial regulatory change to the US pharmaceutical distribution sector in decades, reshaping how every link in the supply chain operates.